InnoSer

@InnoSer1

InnoSer is a young and innovative CRO, supporting biomedical companies in the fields of oncology, neurodegenerative, cardiovascular, and kidney diseases.

Vrijeme pridruživanja: listopad 2012.

Tweetovi

Blokirali ste korisnika/cu @InnoSer1

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @InnoSer1

  1. prije 23 sata

    "We are happy to expand our services on neurodegenerative diseases to cover Parkinson’s disease", thanks to our new partnership with OrganoTherapeutics. Learn more at

    Poništi
  2. 3. velj

    We combine in-vitro and in-vivo methods in several therapeutic fields. Do you work on , , , or ? Send us a short description of your project at info@innoserlaboratories.com and learn more about our applications!

    Poništi
  3. 29. sij

    We are expanding our network and capabilities with strategic partnerships. Most recently, we joined forces with to serve the combined global customer base from both companies better. Learn more about this partnership at

    Poništi
  4. proslijedio/la je Tweet
    27. sij

    Dr. Alex Bastiaens sharing their work on brain-on-a-chip technology for disease modeling, thriving on cross-sectoral collaborations.

    Poništi
  5. 24. sij

    Next week we'll be at 's Diatech 2020. Come talk to us about our in-vitro disease models including and don't miss our affiliated consortium partner's presentation. Learn more about their work at (image: Luttge group )

    Poništi
  6. 21. sij

    Last week, we had a monocyte activation testing (MAT) training together with our partner . By offering our pyrogen detection services we will soon provide a robust alternative to testing in animals.

    Poništi
  7. 17. pro 2019.

    Past year has been a year of collaboration and growth for InnoSer. Together with you, we’re hoping to progress even further in 2020. We wish you and your family happy holidays, and a healthy new year.

    Poništi
  8. 29. stu 2019.

    Monocyte activation test received media coverage this week. By our recent collaboration with and , we are proud to offer services that save not only human but also rabbit and crab lives. 🐰🦀

    Poništi
  9. 14. stu 2019.

    Thank you for talking to us at ASN and Congress. The latter event also became the debut with our new partners and introducing our monocyte activation testing services. Learn more at

    Poništi
  10. 23. lis 2019.

    InnoSer's ADPKD mouse model offers unique possibilities for kidney disease research. Come meet us during 's Kidney Week to learn more.

    Poništi
  11. 17. lis 2019.

    We are adding diseases to our fields of expertise. Our work on delivering a brain-on-a-chip technology is only at its infancy, but will eventually provide a platform optimal for drug development. Read more 👉

    Poništi
  12. proslijedio/la je Tweet
    10. lis 2019.

    Also represented during explaining their organoid technology as a promising strategy for

    Poništi
  13. 9. lis 2019.

    [WE ARE EXPANDING] Soon, InnoSer will start operating in its new facilities in addition to existing ones, to offer better services. Learn more about our offerings @

    Poništi
  14. proslijedio/la je Tweet
    Poništi
  15. 27. ruj 2019.

    InnoSer is happy to attend the Biomedica On the Move meeting in Geleen this October and is looking forward to building bridges with other and companies. Will you be there too? Feel welcomed to exchange views with us!

    Poništi
  16. 10. pro 2018.

    On behalf of the InnoSer Team I am very proud to announce a major achievement and key strategic development. Please find attached our latest newsletter about "Leap into the future; Development of a PDXO drug screening platform."

    Poništi
  17. 9. lis 2018.
    Poništi
  18. 7. lis 2018.
    Poništi
  19. 25. ruj 2018.
    Poništi
  20. 25. ruj 2018.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·